Aerie Pharmaceuticals Reports Topline Result from Rhopressa Mechanism of Action Study

Aerie Pharmaceuticals (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, today announced topline efficacy results from a double-masked, randomized, placebo-controlled study (AR-13324-CS206; NCT03233308) designed to evaluate the effect of Rhopressa (netarsudil ophthalmic solution) 0.02% on aqueous humor dynamics in patients with open-angle glaucoma or ocular hypertension.

As quoted in the press release:

The study enrolled patients who were diagnosed with open-angle glaucoma or ocular hypertension in both eyes, with unmedicated baseline IOP between 20 and 30 mmHg (millimeters of mercury). The primary endpoint of the study was the mean change from baseline in the mean diurnal outflow facility, measured using previously published methods.¹

In the study, Rhopressa produced a statistically significant increase in trabecular outflow facility of approximately 35 percent over baseline. A complete analysis of the study data will be presented at a future scientific congress.

“Elevated IOP in open-angle glaucoma is due to dysfunction of the trabecular outflow pathway. This study confirms that in patients with elevated IOP, Rhopressa lowers IOP by increasing trabecular outflow facility,” said Casey C. Kopczynski, Ph.D., Chief Scientific Officer, Aerie Pharmaceuticals. “We believe this will give physicians additional confidence that Rhopressa targets the tissue responsible for elevated IOP in their patients, and it will help them understand their options for combining this novel trabecular outflow drug with other therapies that lower IOP through different mechanisms.”

Click here to read the full press release.